Murilo Garrigós

Murilo Garrigós

Instituto do Cérebro, Hospital Israelita Albert Einstein, São Paulo, Brazil
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2024 in Einstein (São Paulo)
Verified
Journal Article
Open access
PDF file
MGMurilo Garrigós
Murilo Garrigós
Fernando Anselmo de OliveiraFernando Anselmo de Oliveira
Fernando Anselmo de Oliveira
CCCícero Júlio Silva Costa
Cícero Júlio Silva Costa
LRLucas Renan Rodrigues
Lucas Renan Rodrigues
Mariana Penteado NucciMariana Penteado Nucci
Mariana Penteado Nucci
Lionel F. GamarraLionel F. Gamarra
Lionel F. Gamarra
Highlights One-step synthesis provides affordable, stable, and biocompatible nanoparticles. PEG-coated gold nanoparticles exhibited very low cytotoxicity effects. This in vivo study did not reveal hematopoietic, renal, or hepatic alterations. The histopathological analysis did not present any tissue or cellular damage. ABSTRACT Objective: To evaluate the in vitro and in vivo toxicities of polyethylene glycol-coated gold nanoparticles synthesized using a one-step process. Methods: Gold nanoparticles were prepared via a co-precipitation method using polyethylene glycol, and the synthesis product was characterized. For

26 August 2022 in World Journal of Stem Cells
Verified
Journal Article
Open access
MGMurilo Garrigós
Murilo Garrigós
Fernando Anselmo de OliveiraFernando Anselmo de Oliveira
Fernando Anselmo de Oliveira
Mariana Penteado NucciMariana Penteado Nucci
Mariana Penteado Nucci
LNLeopoldo Penteado Nucci
Leopoldo Penteado Nucci
AAArielly da Hora Alves
Arielly da Hora Alves
Lionel F. GamarraLionel F. Gamarra
Lionel F. Gamarra
Bone marrow transplantation (BMT) can be applied to both hematopoietic and nonhematopoietic diseases; nonetheless, it still comes with a number of challenges and limitations that contribute to treatment failure. Bearing this in mind, a possible way to increase the success rate of BMT would be cotransplantation of mesenchymal stem cells (MSCs) and hematopoietic stem cells (HSCs) to improve the bone marrow niche and secrete molecules that enhance the hematopoietic engraftment. To analyze HSC and MSC characteristics and their interactions through cotransplantation in murine models. We searched for original articles indexed in PubMed and Scopus during the last decade that used HSC and MSC cotransplantation and in vivo BMT in animal models while evaluating cell engraftment. We excluded in vitro studies or studies that involved graft versus host disease or other hematological diseases and publications in languages other than English. In PubMed, we initially identified 555 articles and after selection, only 12 were chosen. In Scopus, 2010 were identified, and six were left after the screening and eligibility process. Of the 2565 articles found in the databases, only 18 original studies met the eligibility criteria. HSC distribution by source showed similar ratios, with human umbilical cord blood or animal bone marrow being administered mainly with a dose of 1 × 107 cells by intravenous or intrabone routes. However, MSCs had a high prevalence of human donors with a variety of sources (umbilical cord blood, bone marrow, tonsil, adipose tissue or fetal lung), using a lower dose, mainly 106 cells and ranging 104 to 1.5 × 107 cells, utilizing the same routes. MSCs were characterized prior to administration in almost every experiment. The recipient used was mostly immunodeficient mice submitted to low-dose irradiation or chemotherapy. The main technique of engraftment for HSC and MSC cotransplantation evaluation was chimerism, followed by hematopoietic reconstitution and survival analysis. Besides the engraftment, homing and cellularity were also evaluated in some studies. The preclinical findings validate the potential of MSCs to enable HSC engraftment in vivo in both xenogeneic and allogeneic hematopoietic cell transplantation animal models, in the absence of toxicity.

3 March 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MGMurilo Garrigós
Murilo Garrigós
Fernando Anselmo de OliveiraFernando Anselmo de Oliveira
Fernando Anselmo de Oliveira
Mariana Penteado NucciMariana Penteado Nucci
Mariana Penteado Nucci
JMJavier Bustamante Mamani
Javier Bustamante Mamani
ODOlívia Dias
Olívia Dias
Lionel F. GamarraLionel F. Gamarra
Lionel F. Gamarra
Bone marrow transplantation is a treatment for a variety of hematological and non-hematological diseases. For the transplant success, it is mandatory to have a thriving engraftment of transplanted cells, which directly depends on their homing. The present study proposes an alternative method to evaluate the homing and engraftment of hematopoietic stem cells using bioluminescence imaging and inductively coupled plasma mass spectrometry (ICP-MS) associated with superparamagnetic iron oxide nanoparticles. We have identified an enriched population of hematopoietic stem cells in the bone marrow following the administration of Fluorouracil (5-FU). Lately, the cell labeling with nanoparticles displayed the greatest internalization status when treated with 30 µg Fe/mL. The quantification by ICP-MS evaluate the stem cells homing by identifying 3.95 ± 0.37 µg Fe/mL in the control and 6.61 ± 0.84 µg Fe/mL in the bone marrow of transplanted animals. In addition, 2.14 ± 0.66 mg Fe/g in the spleen of the control group and 2.17 ± 0.59 mg Fe/g in the spleen of the experimental group was also measured. Moreover, the bioluminescence imaging provided the follow up on the hematopoietic stem cells behavior by monitoring their distribution by the bioluminescence signal. Lastly, the blood count enabled the monitoring of animal hematopoietic reconstitution and ensured the transplantation effectiveness.